Abstract
Since May 2022, monkeypox cases have been reported in non-endemic countries, and the disease was declared a Public Health Emergency of International Concern. Rapid identification of new cases is critical for outbreak control. Environmental surveillance can be used as a complementary tool for detecting pathogens circulating in communities. This study aimed to investigate whether Monkeypox DNA can be detected in wastewater from a transportation hub.
Twenty samples were collected in Italy’s first airport in Rome and tested using published and modified real-time PCR assays targeting the G2R region (TFN gene), F3L, and N3R genes. Nested PCR assays were also used for confirmation by sequencing. Three samples tested positive by real-time PCR and/or by nested PCR, confirming the occurrence of the virus in the airport’s wastewater.
Wastewater surveillance can be quickly adapted to investigate emerging threats and can be used to track the introduction and/or the diffusion of the Monkeypox virus in communities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was partially supported by collaboration agreement EC G.A. NO. 060701/2021/864481/ SUB/ ENV.C2 - Support to Member States for the creation of systems, local collection points and digital infrastructures for monitoring COVID 19 and its variants in wastewater - Italy.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.